The efficacy of acalatinib/acalatinib

Acalabrutinib/Acalabrutinib is a highly selective and potent Bruton tyrosine kinase (BTK) inhibitor that inhibits its activity by binding to the carbene of BTK. It is used to treat mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In B cells, the activation of the BTK signaling pathway is closely related to processes such as B cell proliferation, trafficking, chemotaxis, and adhesion. Two major studies showed acotinib was effective in delaying death or disease progression.

One of the studies, involving535 patients who had not received prior treatment for chronic lymphocytic leukemia (CLL), compared acotinib or acotinib with obinutuzumab About 28 months after combining Otuzumab with another cancer drug, chlorambucil, 8% of patients who took the combination died or their cancer worsened, compared with 15% of those who took the combination alone or 53% of those who took the combination.

The second major study, involving 310 patients, compared acotinib alone with a combination of other cancer drugs (rituximab and idelalisib or bendamustine) in patients whose CLL disease had relapsed or failed to respond to previous treatments. After about 16 months, 17% of patients who received acotinib died or their cancer worsened, compared with 44% of patients who received the rituximab combination. This indicates that acotinib monotherapy can achieve better efficacy.

In general, acotinib, as a new type of BTK inhibitor, has shown good efficacy in treating the above diseases. By inhibiting the activity of the BTK signaling pathway in B cells, it can delay disease progression and reduce mortality or cancer progression. However, further research is needed to verify its long-term efficacy and safety to better provide treatment options for patients.